Inmed Pharmaceuticals Inc. (INM) has released an update.
InMed Pharmaceuticals Inc. has announced promising preclinical results for INM-901, a potential treatment for Alzheimer’s disease, demonstrating reduced neuroinflammation and improved neuronal function. The treatment acts as a preferential signaling agonist for CB1 and CB2 cannabinoid receptors, as well as affecting the PPAR signaling pathway, which could address various pathological factors of the disease. These findings suggest INM-901 has multiple mechanisms that could contribute to neuroprotection and cognitive improvements in Alzheimer’s patients.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
